36.00
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally - AOL.com
KOD Technical Analysis | Trend, Signals & Chart Patterns | KODIAK SCIENCES INC (NASDAQ:KOD) - ChartMill
Kodiak Sciences Inc stock (US50012K1051): earnings loss widens as biotech pushes retina pipeline - AD HOC NEWS
Kodiak Sciences Inc stock (US50012K1051): what’s behind the latest volatility after eye disease se - AD HOC NEWS
Boxer Capital Management Boosts Kodiak Sciences Holdings in Q1 2026News and Statistics - IndexBox
Kodiak Sciences Inc stock (US50012K1051): Investors eye eye-disease pipeline after latest company up - AD HOC NEWS
Kodiak Sciences stock hits 52-week highhere's why - MSN
Kodiak Sciences (KOD) price target increased by 16.91% to 66.30 - MSN
Sirenia Capital (KOD) and Alex Silverstein report 3,495,000 shares (5.7%) - Stock Titan
Kodiak Sciences stock (US50012K1051): Q4 2025 earnings miss sparks investor focus - AD HOC NEWS
Kodiak Sciences (KOD) up 2% since last earnings report: Can it continue? - MSN
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $56 - Moomoo
Number of shareholders of Kodiak Sciences Inc – NASDAQ:KOD - TradingView
Chardan Capital upgrades Kodiak Sciences (KOD) - MSN
TradingKey - TradingKey
Kodiak Sciences stock is surging Friday: What's driving the action? - MSN
KOD Upgraded by Chardan Capital -- Price Target Raised to $61.00 - GuruFocus
This Pitney Bowes Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Chardan upgrades Kodiak Sciences stock rating on drug trial results By Investing.com - Investing.com South Africa
Chardan upgrades Kodiak Sciences stock rating on drug trial results - Investing.com
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58 - Moomoo
Kodiak's Q1 loss wider than expected, pipeline development in focus - MSN
A Look At Kodiak Sciences (KOD) Valuation After Positive Phase 3 GLOW2 Results For Zenkuda - Yahoo Finance
Zenkuda Phase 3 Win and Expanding Pipeline Might Change The Case For Investing In Kodiak Sciences (KOD) - Yahoo Finance
Kodiak Sciences Zenkuda Data Shifts Focus To Retinal Pipeline Value - Sahm
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus - The Globe and Mail
KOD SEC FilingsKodiak Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Cuts Target Price to $65 - Moomoo
Kodiak Sciences 1Q Loss/Shr 94c >KOD - Moomoo
Kodiak Sciences : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Kodiak Sciences (NASDAQ: KOD) Q1 loss deepens as cash runway, going concern risk flagged - Stock Titan
Kodiak Sciences (NASDAQ: KOD) posts Q1 loss, highlights strong Phase 3 data - Stock Titan
Kodiak Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
KOD Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Press Release: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results - Moomoo
Kodiak Sciences (KOD) Expected to Announce Earnings on Wednesday - MarketBeat
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences - marketscreener.com
Kodiak Sciences Inc. $KOD Stock Holdings Decreased by RIA Advisory Group LLC - MarketBeat
Eye drug data from Taiwan cohort backs Kodiak Phase 3 expansion - Stock Titan
Kodiak Sciences Presents Pipeline Advances and KSI-101 Clinical Data At Scientific Conferences - marketscreener.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):